Results

Total Results: 1,524 records

Showing results for "drugs".

341. Comparative Effectiveness and Safety of New Therapies (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-glucose-control_research.pdf
     July 01, 2010 - Exenatide, manufactured as Byetta by Amylin Pharmaceuticals, Inc. … Additionally, a separate, linkable file is available which includes pharmacy claims for prescription drugs … In Table 3, we provide details about the other drugs for DM used by these patients. … Experts weigh in on promotion, prescription of off-label drugs. JAMA 2007;297:683-684. 15.

342. Slide 1 (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/marketing_evidence_evans.ppt
     September 13, 2006 - evidence” to healthcare consumers: Applying social marketing to evidence about the harms and benefits of pharmaceuticals … Agency for Healthcare Research and Quality Conference: Communicating Harms and Benefits of Prescription Drugs … information to counter the effects of marketing by companies with competing interests (e.g., tobacco, pharmaceuticals … promotion tool Evidence-based AED Dissemination Model Potential Lessons for Health Care Pharmaceuticals … Agency for Healthcare Research and Quality Conference: Communicating Harms and Benefits of Prescription Drugs

343. Improving Medication Safety in High Risk Medicare Beneficiaries Toolkit (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/medication-therapy-management-1_research.pdf
     July 01, 2012 - In isolation, identifying specific drugs to avoid is not sufficient for improving safety. … Drugs 2009;69(4):393-406. 21. Touchette DR, Burns AL, Bough MA, et al. … Different brand name drugs have different Orange Book AB ratings, and generics vary in their combination … If so, with what drugs and what was the reaction? 2. What is your height? 3. … C4.6 C4.7 C4.8 C4.9 C4.10 Patient forgets to use/take drug Patient has concerns with drugs

344. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/vte-prophyalaxis_research-protocol.pdf
     March 01, 2011 - Pharmacologic Agents and Medical Devices Used for Thromboprophylaxis There are a number of antithrombotic drugs … We will evaluate drugs and devices that currently are available in the United States and either are … optimal choice of therapy among burn centers. 17 There is considerable uncertainty around specific drugs … of pharmacologic prophylaxis among patients at the extremes of weight and will assess the optimal drugs … Ballerup, Denmark: LEO Pharmaceutical Products; 2008.

345. PREGNANCY, INCLUDING PRETERM BIRTH #12 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pregnancy-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the

346. PREGNANCY, INCLUDING PRETERM BIRTH #12 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pregnancy-horizon-scan-high-impact-1306.pdf
     June 11, 2013 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … In the health care sector, horizon scanning pertains to identifying new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the

347. S23 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s23.pdf
     October 01, 2007 - Relative Risk, Number Needed to Harm, Frequency Information, and Public Health Impact for Selected Drugs … Drug Discovery, Development, and Translation Work- shop 2: Understanding the Benefits and Risks of Pharmaceuticals … Yale Study Parks FDA Review of Cold Drugs. The Yale Herald News Online 2000. … Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia:

348. Development of Harmonized Outcome Measures for Use in Patient Registries and Clinical Practice: Methods and Lessons Learned (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/white-paper-standardized-library.pdf
     February 01, 2019 - https://www.fda.gov/AboutFDA/CentersOffices/Offi ceofMedicalProductsandTobacco/CDRH/ CDER monitors drugs … Also, efforts to combine drugs (e.g., adding antipsychotic to antidepressant). … Several novel drugs are being studied in trials currently. … for more than $20 billion in direct and indirect expenses each year in the US§§ Treated with pharmaceuticals … Antidepressants Anti-seizure drugs Botox Alternative medicine, including acupuncture, biofeedback

349. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1406.pdf
     June 01, 2014 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … Autism treatments and drugs. [internet].

350. Off-Label Use of Atypical Antipsychotics: An Update | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/atypical-antipsychotics-off-label-update/research

351. CER 173 Executive Summary: Diabetes Medications for Adults With Type 2 Diabetes: An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_executive.pdf
     January 01, 2015 - medications have also emerged, which could change the balance of benefit and risk attributable to these drugs … While we did not combine studies in which individual drugs were found to be a clinical or statistical … Takeda Pharmaceuticals America. … Incretin mimetic drugs for type 2 diabetes: early communication - reports of possible increased risk … www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed July 25, 2015. 72.

352. Crosscutting-Horizon-Scan-High-Impact-1512 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Results The table below lists four topics for which (1) preliminary phase III data for drugs were … Now, Proteus is collaborating with Otsuka Pharmaceuticals Co., Ltd. … It differentiated 100% of multiple drugs and doses taken simultaneously by type and by dose. … Proteus is collaborating with Otsuka Pharmaceuticals Co., Ltd., (Tokyo, Japan) to integrate sensors

353. Topic 0549 Diagnosis and Management of Gout NSD _SJ Clean (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0648-140819.pdf
     June 24, 2014 - interventions (e.g., dietary therapies) and pharmacotherapeutics (e.g., non-steroidal anti-inflammatory drugs

354. Treatments for Acute Pain: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-protocol-acute-pain-treatments.pdf
     August 08, 2019 - therapy versus: 1) nonopioid pharmacologic therapy (e.g., acetaminophen, nonsteroidal anti-inflammatory drugs … effectiveness of nonopioid pharmacologic therapy (e.g., acetaminophen, nonsteroidal anti-inflammatory drugs … nonopioid pharmacological therapy used for acute pain (acetaminophen, nonsteroidal anti-inflammatory drugs … Opioid analgesics—risky drugs, not risky patients. … A systematic review and meta-analysis comparing the efficacy of nonsteroidal anti-inflammatory drugs

355. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/psoriasis-chronic_research-protocol.pdf
     January 10, 2012 - approaches to psoriasis treatment. 4,5,11 Biologic therapies for psoriasis use genetically engineered drugs … systemic therapy or phototherapy Etanercept Enbrel ® (injectable) Amgen, Inc. and Wyeth Pharmaceuticals … (Schwarz Pharma Manufacturing; OSI Pharmaceuticals Inc.) … Teva Pharmaceuticals USA (Barr Pharmaceuticals) Symptomatic control of severe, recalcitrant, … oral capsule) GlaxoSmithKline (CatalentPharmaSo lutions;Accucaps Industries, Ltd.; Banner Pharmaceuticals

356. REQUEST FOR TASK ORDER (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-end-of-life-quality-meaures_research.pdf
     April 01, 2010 - New chemotherapy regimen was defined only for the retrospective cohort using Medicare J-codes for drugs … used by Earle.8 Additional J-codes for chemotherapy were identified for chemotherapy drugs that had … • PACE/ PAAD NDC codes for drugs listed in Appendix 2. … • PACE/ PAAD NDC codes for drugs listed in Appendix 2. … • PACE/ PAAD NDC codes for drugs listed in Appendix 2.

357. Multiple-Sclerosis Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/multiple-sclerosis_executive.pdf
     April 01, 2015 - The overview and network analysis were too recent to include the newest approved drugs, such as fingolimod … to correlate with the frequency and severity of side effects.7 The injectable treatments, the IFN drugs … There are no class A drugs (drugs safe for use during pregnancy according to the FDA) for MS. … one that is more effective or more tolerable, and studies have found high rates of switching between drugs … Newly approved drugs, such as fingolimod, and drugs in the development pipeline are emphasizing oral

358. Disposition of Comments Report for Treatment of Depression During Pregnancy and the Postpartum Period (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/depression-pregnancy-postpartum_disposition-comments.pdf
     July 08, 2014 - #10 ES 5 (p. 13) Interventions Reword 2nd sentence to avoid using double “nots” Changed to: “Drugs … risk of neonatal withdrawal symptoms or pulmonary hypertension with maternal use of antidepressant drugs … to improve some symptoms based on evidence in nonpregnant patients, it is possible that individual drugs … to improve some symptoms based on evidence in nonpregnant patients, it is possible that individual drugs … to improve some symptoms based on evidence in nonpregnant patients, it is possible that individual drugs

359. Comparative Effectiveness Review Disposition of Comments Report: Anxiety in Children (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/disposition-of-comments-cer-192-anxiety-in-children.pdf
     August 31, 2017 - 2017 Commentator & Affiliation Section Comment Response TEP 2 Methods p. 15 CBT vs Drugs … Results Page 25, key points: the authors might clarify that both of the RCTs comparing CBT to drugs … At a minimum, it would be helpful to indicate what class of drugs each comparison comes from (e.g. … For example, in the section “CBT combined with drugs” and subsection “Sertraline vs. … Of note, the original Walkup et al. 2008 study is cited in other comparisons of interest (drugs versus

360. Disposition of Comments for Treatments for Seasonal Allergic Rhinitis (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/allergy-seasonal_disposition-comments.pdf
     July 17, 2013 - This has been corrected in the “Description of Included Studies” for this comparison, in Table 10 (Drugs … in pregnancy at least for orally inhaled cromolyn Sentence revised to list Pregnancy Category B drugs … : “Preferred treatments are Pregnancy Category B drugs (nasal cromolyn, budesonide, and ipratropium … before an intranasal corticosteroid or an intranasal antihistamine to increase delivery of these drugs … before an intranasal corticosteroid or an intranasal antihistamine to increase delivery of these drugs